Ownership Action Don’t Lie: Incyte Corp (NASDAQ:INCY) Q2 2016 Sentiment Change

November 30, 2016 - By Adrian Mccoy   ·   0 Comments

Ownership Action Don't Lie: Incyte Corp (NASDAQ:INCY)  Q2 2016 Sentiment Change

Sentiment for Incyte Corp (NASDAQ:INCY)

Incyte Corp (NASDAQ:INCY) institutional sentiment decreased to 1.15 in Q2 2016. Its down -0.04, from 1.19 in 2016Q1. The ratio has worsened, as 176 investment managers increased and opened new stock positions, while 148 sold and trimmed stakes in Incyte Corp. The investment managers in our partner’s database now own: 172.01 million shares, down from 181.27 million shares in 2016Q1. Also, the number of investment managers holding Incyte Corp in their top 10 stock positions decreased from 8 to 7 for a decrease of 1. Sold All: 32 Reduced: 116 Increased: 131 New Position: 45.

Incyte Corporation is a biopharmaceutical company. The company has a market cap of $19.66 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. It has a 139.79 P/E ratio. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases .

About 69,263 shares traded hands. Incyte Corporation (NASDAQ:INCY) has risen 43.56% since April 27, 2016 and is uptrending. It has outperformed by 38.33% the S&P500.

Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on February, 9. They expect $0.18 earnings per share, down 37.93% or $0.11 from last year’s $0.29 per share. INCY’s profit will be $33.87M for 145.10 P/E if the $0.18 EPS becomes a reality. After $0.11 actual earnings per share reported by Incyte Corporation for the previous quarter, Wall Street now forecasts 63.64% EPS growth.

According to Zacks Investment Research, “Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.”

Baker Bros. Advisors Lp holds 19.7% of its portfolio in Incyte Corporation for 23.50 million shares. Bb Biotech Ag owns 3.84 million shares or 12.12% of their US portfolio. Moreover, Rtw Investments Llc has 10.72% invested in the company for 392,236 shares. The Maryland-based Brown Capital Management Llc has invested 3.35% in the stock. Capital International Ltd Ca, a California-based fund reported 506,416 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 8 insider sales for $13.79 million net activity.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Ratings analysis reveals 89% of Incyte’s analysts are positive. Out of 19 Wall Street analysts rating Incyte, 17 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $85 while the high is $146. The stock’s average target of $109.44 is 4.76% above today’s ($104.47) share price. INCY was included in 39 notes of analysts from August 6, 2015. The rating was initiated by Suntrust Robinson with “Buy” on Friday, August 5. Brean Capital maintained the stock with “Buy” rating in Wednesday, August 5 report. The rating was maintained by Oppenheimer on Monday, November 9 with “Outperform”. As per Wednesday, August 12, the company rating was downgraded by Zacks. As per Wednesday, July 13, the company rating was initiated by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, November 4 by UBS. BMO Capital Markets initiated Incyte Corporation (NASDAQ:INCY) on Thursday, April 7 with “Outperform” rating. The stock has “Overweight” rating given by Morgan Stanley on Wednesday, March 23. The stock has “Hold” rating given by Jefferies on Wednesday, October 5. Goldman Sachs initiated the shares of INCY in a report on Wednesday, November 18 with “Buy” rating.

INCY Company Profile

Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Firm has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia.

Another recent and important Incyte Corporation (NASDAQ:INCY) news was published by Schaeffersresearch.com which published an article titled: “Analyst Upgrades: Microsoft Corporation, Incyte Corporation, and NetApp Inc.” on November 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>